The development of intranasal vaccine using liposomes against fungal infections

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K18935
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy
• Research Institution: Tokyo University of Pharmacy and Life Science
• Principal Investigator: Tada Rui 東京薬科大学, 薬学部, 講師 (70635888)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 粘膜ワクチン / 真菌感染症 / リポソーム / 粘膜アジュバント

Outline of Final Research Achievements

Mucosal vaccine systems are a promising therapeutic strategy for preventing and/or treating fungal infection, which is increasingly becoming associated with immunosuppressive conditions. We have recently found that intranasal administration of an antigenic protein with the DOTAP/DC-chol liposomes induced antigen-specific mucosal and systemic antibody responses in mice. Here, we attempted to develop a cationic liposome-based nasal vaccine against invasive fungal infections. As results, intranasal administration of DOTAP/DC-chol liposomes with CaSap2p and AfAspf3p, which are derived from Candida albicans and Aspergillus fumigatus, respectively, induced antigen-specific mucosal IgA, systemic IgG, Th17 immune responses in mice.

Free Research Field

薬剤学、免疫学